January 2025 in “International Journal of Advanced Biochemistry Research” Nexgard successfully treated a husky's demodicosis.
1 citations
,
June 2015 in “Australasian Journal of Dermatology” A patient with Cronkhite-Canada syndrome improved with nutritional support and steroids, but early diagnosis is key due to high mortality.
56 citations
,
January 2023 in “Genes & Diseases” Repurposing existing drugs and using micronutrients may effectively target cancer stem cells and improve cancer treatment.
6 citations
,
November 2022 in “Journal of autoimmunity” JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.
22 citations
,
March 2017 in “Transplant Infectious Disease” Leflunomide successfully treated a rare skin condition in a liver transplant patient.
March 2017 in “DOAJ (DOAJ: Directory of Open Access Journals)” Antioxidants helped reduce prednisolone dosage and improved hair growth in alopecia areata patients.
January 2016 in “대한피부과학회지” Bortezomib chemotherapy can cause temporary skin rashes.
TCA injections are more effective and safer than cryotherapy for treating alopecia areata.
January 2023 in “National Journal of Physiology, Pharmacy and Pharmacology” Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.
2 citations
,
January 2025 in “Сибирский научный медицинский журнал” TS-13 effectively stops tumor growth and reduces chemotherapy side effects.
June 2024 in “Australasian Journal of Dermatology” Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
New treatments for skin diseases in 1979 showed promising results with fewer side effects.
Topical corticosteroids are effective for skin conditions but can have side effects.
January 2010 in “Journal of Animal Science” Transcutaneous vaccination using nanoparticles can enhance immune responses and reduce basal cell carcinomas.
Tofacitinib helped a woman with total-body hair loss grow her hair back.
January 2019 in “프로그램북(구 초록집)” Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
13 citations
,
July 2011 in “Journal of Dermatological Treatment” Clobetasol and pimecrolimus are similarly effective for alopecia areata, but pimecrolimus has fewer side effects and is preferred for long-term use.
6 citations
,
December 2015 in “Medicine” Cronkhite-Canada syndrome may be more treatable and less severe than previously thought.
January 2026 in “Cell and Tissue Biology” TS-13 speeds up hair regrowth after chemotherapy without affecting treatment effectiveness.
November 2023 in “Pakistan Journal of Health Sciences” Clobetasol propionate 0.05% is more effective for hair re-growth in alopecia areata than tacrolimus 0.1%.
5 citations
,
May 2015 in “The Journal of Dermatology” Topical corticosteroids can help treat severe alopecia areata when other treatments fail.
July 2025 in “Journal of Investigative Dermatology” Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.
1 citations
,
November 2022 in “Journal of Investigative Dermatology” ALRN-6924 may prevent hair loss caused by chemotherapy.
5 citations
,
April 2019 in “Veterinary Dermatology” Cats infested with Lynxacarus radovskyi can lose hair without inflammation, treatable with selamectin.
168 citations
,
December 1986 in “Cancer Chemotherapy and Pharmacology” Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.
June 2016 in “Journal of Coastal Life Medicine” The terrier dog with pituitary-dependent hyperadrenocorticism was successfully treated with mitotane.
33 citations
,
May 2017 in “Journal of Clinical Oncology” ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
November 2024 in “Journal of Investigative Dermatology” Paclitaxel chemotherapy causes premature aging and damage to hair follicles, potentially leading to permanent hair loss.
9 citations
,
July 2022 in “Journal of Clinical Oncology” Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.
April 2018 in “Journal of Investigative Dermatology” The role of γδT-cells in causing alopecia areata remains unclear.